[AACR] Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3¦Â Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies |
Reward30points
Best Answer
2024-2-6
|
| |
50
Abstract 4237: Social isolation induces gut dysbiosis, mitochondrial metabolic dysfunction, and infiltration of tumor immunosuppressive cells: Do they explain enhanced mammary tumorigenesis
20
An Antitumor T-cell Response Was Induced by Engineered Commensal Bacteria
30
Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions
30
Abstract LB066: Machine learning algorithm for drug discovery targeting new co-transcription factors of HIF1A
30
Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells.
